Aristeia Capital’s Starling Oncology STLN Stock Holding History

Aristeia Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-62,500	Closed	-$622K	–	550
2021 Q2	$622K	Buy	+62,500	New	+$629K	0.01%	375

Other funds holding STLN

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Omni Partners US Irvine, California $1.95B AUM

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital's STLN Position: Q3 2021 in Review

Aristeia Capital sold out of Starling Oncology (STLN) in Q3 2021, closing a stake of 62,500 shares — an estimated $622K sold.

Aristeia Capital first reported a position in STLN in Q2 2021 and held it in 1 quarter. The position peaked at $622K in Q2 2021. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

Aristeia Capital reported no remaining Starling Oncology position as of Q3 2021 after selling out during the quarter.
Aristeia Capital sold 62,500 Starling Oncology shares in Q3 2021, an estimated $622K.
Aristeia Capital first reported a position in Starling Oncology in Q2 2021 and held it in 1 quarter.
Aristeia Capital's Starling Oncology position peaked at $622K in Q2 2021.
51 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2021.

Based on Aristeia Capital's 13F filing for Q3 2021, filed 15 Nov 2021.